▶ 調査レポート

製薬のジンバブエ市場2021-2026:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Zimbabwe Pharmaceutical Market - Growth, Trends, COVID-19 Impact and Forecasts (2021 - 2026)

Mordor Intelligenceが調査・発行した産業分析レポートです。製薬のジンバブエ市場2021-2026:成長・動向・新型コロナの影響・市場予測 / Zimbabwe Pharmaceutical Market - Growth, Trends, COVID-19 Impact and Forecasts (2021 - 2026) / MRC2108A498資料のイメージです。• レポートコード:MRC2108A498
• 出版社/出版日:Mordor Intelligence / 2021年7月
• レポート形態:英文、PDF、70ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥357,500 (USD3,250)▷ お問い合わせ
  Team User¥412,500 (USD3,750)▷ お問い合わせ
  Corporate License¥715,000 (USD6,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社は、製薬のジンバブエ市場規模が2021年から2026年の間に4.2%成長すると予測しています。本調査資料では、ジンバブエの製薬市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、カテゴリー別分析、処方別分析、競争状況、市場機会/将来の見通しなどを掲載しています。

The Zimbabwe Pharmaceutical Market is expected to register a CAGR of 4.2% over the forecast period (2021-2026).

The impact of the COVID-19 outbreak on the Pharmaceutical industry in Zimbabwe has been significant as there has been an increased demand for therapeutics in the treatment of COVID-19 infected patients, which further led to an increase in the large scale manufacturing of pharmaceuticals products in the country. However, the supply chain between the other regions of the globe and the country was disrupted due to lockdown measures and thus, local manufacturers played a critical role during the COVID-19 pandemic. According to the research article titled “Impact of COVID-19 on Supply Chains in Zimbabwe”, published in Journal of Public health International 2020, the disruption of medical supplies such as pharmaceuticals during the pandemic has given a great opportunity for Zimbabwe to be less dependent on the foreign medical supplies, thereby increasing the local manufacturing of therapeutics. Additionally, the Zimbabwean Ministry of Health and ChildCare (MOHCC) has been involved in taking measures to strengthen the country’s ability to produce medical supplies through various organizations such as Varichem, CAPS, Natpharma and Avail Pharmaceuticals during the pandemic. Thus, the above mentioned factors is expected to have a significant impact on the studied market growth.

The Zimbabwe Pharamceutical market is expected to propel due to the factors such as growing burden of geriatric population coupled with the increasing incidence of chronic diseases in the country.

According to the United Nations, World Population Ageing Report, 2019, the population aged 65 years and above in Zimbabwe was estimated to be 437,000 in 2019 and was expected to reach to 1,297,000 by 2050. As the growing elderly population is more prone to chronic diseases such as cardiovascular diseases, cancers, gastrointestinal disorders among others, the demand for the effective and novel therapeutics is expected to surge in the coming years in the country. Thus, the above mentioned factors are anticipated to aid in the growth of the studied market over the forecast period. However the strigent regulatory framework is expected to impede the astudied rket growth.

Key Market Trends

Healthcare Expenditure in Zimbabwe

According to the 2020 Health Budget Brief, Zimbabwe, a capital expenditure allocation was doubled from 15% in 2019 to 32% in 2020 on healthcare, as a share of the total annual budget of the country. Health outcomes in the country were found to be witnessing an improvement over the past few years, and the country had positive results on most of the healthcare indicators over the past 5 years. The percentage of children that received vaccinations in the country rose from 69.2 percent in 2014 to 76% in 2019. Also, the maternal mortality rate dropped significantly from 614 deaths per 100,000 live births in 2014 to 462 in 2019 in Zimbabwe. Thus, the growing healthcare expenditure coupled with healthcare initiatives by Government and Non-profit organizations is expected to drive the growth of the pharmaceutical market in Zimbabwe over the forecast period.

Prescription Drugs segment Holds the Largest Share and Expected to do Same in the Forecast Period

The prescription Drugs segment in the Zimbabwe Pharmaceutical market is expected to hold a major share and is expected to witness significant growth in the forecast period. The major drivers for the growth of the prescription drugs segment include the increasing research and development activities by key players for the launch of new products aimed at treating various illness, growing geriatric population, rising prevalence of chronic diseases such as cardiovascular disease, cancer, autoimmune disease, coupled with growing awareness on the use of prescription drugs in the country. Cardiovascular disease, cancers, and other chronic diseases are increasing in Zimbabwe, which surges the demand for advanced therapeutics thus driving the market growth. Rising cases of chronic diseases would lead to a rise in the use of prescription drugs that will accelerate demand growth in the country during the forecast period, along with an improvement in per capita healthcare expenditure in the country which is also anticipated to further boost growth during the forecast period.

Competitive Landscape

The Zimbabwe pharmaceutical market is highly competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the Key companies which are currently dominating the market are Datlabs, Pharmanova, Pfizer Inc, Bayer AG, and Zim Laboratories among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.1.1 Healthcare Expenditure (Govt. Vs Private)
4.1.2 Pharmaceutical Imports and Exports
4.1.3 Epidemiology Data For key Diseases
4.1.4 Regulatory Landscape/Regulatory Bodies
4.1.5 Licensing and Market Authorization (For both Local Production and Imported Goods)
4.1.6 Pipeline Analysis
4.1.6.1 By Phase
4.1.6.2 By Sponsor
4.1.6.3 By Disease
4.1.7 Statistical Overview
4.1.7.1 Number of Hospitals
4.1.7.2 Employment in Pharmaceutical Sector
4.1.7.3 R & D Expenditure
4.1.8 Ease of Doing Business
4.2 Market Drivers
4.2.1 Rising Burden of Geriatric population
4.2.2 Increasing Incidence of Chronic Disease
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By ATC/Therapeutic Category
5.1.1 Blood and Hematopoietic Organs
5.1.2 Digestive Organ and Metabolism
5.1.3 Cardiovascular System
5.1.4 Nervous System
5.1.5 Musculoskeletal Organ
5.1.6 General Antiinfectives Systemic
5.1.7 Respiratory System
5.1.8 Others
5.2 By Prescription Type
5.2.1 Prescription Drugs (Rx)
5.2.1.1 Branded
5.2.1.2 Generic
5.2.2 OTC Drugs

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Datlabs
6.1.2 Pharmanova
6.1.3 Bayer AG
6.1.4 GlaxoSmithKline plc
6.1.5 Zim Laboratories Limited
6.1.6 Bristol Myers Squibb Company
6.1.7 Eli Lilly and Company
6.1.8 Novartis AG
6.1.9 Sanofi S.A
6.1.10 Pfizer Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS